Now, amid calls to dramatically expand methadone access, a team of addiction researchers is looking for answers. A new clinical trial, set to launch this year, will attempt to directly compare patients’ ability to remain in treatment when prescribed buprenorphine or methadone in an office setting — the first study of its kind in the fentanyl era.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,